BackgroundBy September 2, 2021, over 30,000 COVID-19-vaccinated females had reported menstrual changes to the MHRA's Yellow Card surveillance system. As a result, the National Institutes of Health (NIH) is urging researchers to investigate the COVID-19 vaccine's effects on menstruation. Therefore, this study was conducted to explore the menstrual changes after COVID-19 vaccination and/or SARS-CoV-2 infection and their interrelations with demographic, mood, and lifestyle factors in Arab women of childbearing age (CBA).MethodologyA cross-sectional study was conducted during October 2021 using an Arabic validated and self-administrated questionnaire. In total, 1,254 Women of CBA in the Arabic Population (15–50 y) with regular menstrual cycles were randomly selected from five countries (Saudi Arabia, Egypt, Syria, Libya, and Sudan).ResultsThe mean (SD) age of the 1,254 studied females was 29.6 (8.5) years old. In total, 634 (50%) were married, 1,104 (88.0%) had a University education or above, 1,064 (84.4%) lived in urban areas, and 573 (45.7%) had normal body weight. Moreover, 524 (41.8%) were COVID-19 cases and 98 women (18.7%) reported menstrual changes (MCs). The 1,044 (83.5%) vaccinated females reported 418 (38.5%) MCs after being vaccinated, and these MCs resolved in 194 women (55.1%) after more than 9 months. Statistically significant relationships were observed between the reported MCs and the following variables: age, marital status, level of education, nationality, residence, and BMI. MCs were reported at 293(80.6) after the 2nd dose, and were mainly reported after 482 (46.1) Pfizer, 254 (24.3) Astrazenica, and 92 (8.8) Senopharm.ConclusionMCs among women of CBA after COVID-19 infection and vaccination are prevalent and complex problems, and had many determinates.

Over six million individuals have died as a result of the infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes Covid-19. The first COVID-19 vaccines were introduced to the public in 2020 through emergency authorizations. This study aims to uncover the fears and misconceptions behind the hesitation or refusal of taking the COVID-19 vaccine in Syria. Methods: Through a nationwide cross-sectional study, a convenience sample of 10006 participants who were at least 18 years old and living in Syria participated in a validated questionnaire during the period between January and May 2022 Results: The majority of recruited individuals were female (n= 6048; 60.4%) from the (18-24) age group (n= 5908; 59%). We recorded 5811 (58%) participants who still have fears and anxieties about the COVID-19 vaccine. The main concerns about vaccines were the rapid development of vaccines (41.4%), fears of blood clots (37.9%), the fears of common side effects (35.2%), and allergic reactions (26.5%). Conclusion: The COVID-19 vaccine is considered the most promising measure for controlling the spread of infection. The success of this policy will depend on the rate of global acceptance of the vaccine. High variability in vaccine acceptance and high vaccine hesitancy can affect the efforts to terminate the COVID-19 pandemic. Addressing the barriers associated with the acceptance of COVID-19 vaccination will be the cornerstone to achieving maximum vaccination coverage. The most common reasons behind refusing the vaccine in Syria were fear of side effects, followed by fears, general concerns, manufacturing-related reasons, and conspiracy belief

Background and Aims: Despite the significant milestone of vaccine discovery, the spread of misinformation and pseudoscientific claims has resulted in an increasing number of people refusing vaccination in Syria. In this study, we aimed to explore fears and misconceptions towards COVID-19 vaccines among the Syrian population.Methods: We conducted a nationwide cross-sectional study between January and May 2022, using a convenience sample of 10,006 participants aged at least 18 years and living in Syria. We administered a validated online/paper questionnaire and conducted face-to-face interviews. We used SPSS software (version 26) for statistical analysis, assessing our data using frequency and χ 2 tests, with p < 0.05 considered statistically significant.Results: The majority of the participants were female 6048 (60.4%), university degree holders 7304 (73%), and from urban areas 8015 (80.1%). Approximately half of the participants 5021 (50.2%) belonged to the medical sector (49% had concerns about the vaccine). Females, university degree holders, and participants with a history of symptomatic COVID-19 were more likely to have fears about the vaccines. The main concerns about the vaccines were the rapid development, fears of blood clots, and common side effects. The prevalence of some misconceptions was relatively high, such as the belief that the vaccine is an experiment or a secret plan to reduce the population. Reliable sources are crucial to fight misleading information on social media. Conclusion: COVID-19 vaccine is key to controlling the spread, but acceptance rate is critical. High variability in vaccine acceptance and high vaccine hesitancy can affect the efforts to terminate the COVID-19 pandemic. Addressing the barriers associated with the acceptance of COVID-19 vaccination will be the cornerstone to achieving maximum vaccination coverage. It is important to consider the reasons for Health Sci. Rep.

Background: In August 2020, a brain chip was announced as implantation in the human brain targeted to boost brain activity without significant side effects. The aim of this work was to examine the level of knowledge, awareness, and public concerns about the use of brain chip implants. Methods: An online cross-sectional survey targeted 326 adults from more than five countries in the Middle East and North Africa during the period from May 2021 to July 2021. The data was collected through a validated self-administrated questionnaire composed of five sections. The collected data were coded and analyzed using suitable tests and methods. Results: According to our results, 54.6% of the study participants mentioned that they had heard about the Brain Chip Implant; while only 6.1% stated that they knew its importance. The most common reported indication for the Brain Chip Implant was improving memory, followed by treatment of epilepsy and improving mental function. Brain Chip Implant safety seemed to be the most common public concern, as most of the participants were hesitant about using it and had concerns regarding its safety.  Conclusion: Medical personnel seems to be the most concerned about the use of the brain chip implant. Safety measures, confidentiality, and security procedures, respectively, are the major issues that might limit the broad use of the brain chip implant.

Dermoid cysts are a rare case of developmental abnormality that results in benign tumors, which are classified into three categories based on their cause and appearance. Dermoid cysts tend to present within the first year after birth and are most commonly diagnosed by the age of 5. A 15-year-old girl presented with a complaint of localized, paroxysmal pain and malodorous fluid oozing from the left shoulder for the last 2 weeks. A fistulogram showed an extension of the fistula behind the clavicle and above the scapula with a cystic formation measuring ~2 cm on the upper part of the fistula tract, which called for appropriate surgical intervention. Our case is the first reported dermoid cyst in the left shoulder area associated with a fistula at birth, which is a rare complication since the complications of dermoid cysts differ depending on their location and size.